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Abstract
Treatment-resistant schizophrenia, affecting approximately 20–30% of patients with schizo-
phrenia, has a high burden both for patients and healthcare services. There is a need to iden-
tify treatment resistance earlier in the course of the illness, in order that effective treatment,
such as clozapine, can be offered promptly. We conducted a systemic literature review of pro-
spective longitudinal studies with the aim of identifying predictors of treatment-resistant
schizophrenia from the first episode. From the 545 results screened, we identified 12 published
studies where data at the first episode was used to predict treatment resistance. Younger age of
onset was the most consistent predictor of treatment resistance. We discuss the gaps in the
literature and how future prediction models can identify predictors of treatment response
more robustly.
Predictors of treatment-resistant schizophrenia: A systematic review of prospective
observational studies
For approximately a third of patients with schizophrenia, standard antipsychotic medications
do not adequately alleviate their psychotic symptoms (Conley and Kelly, 2001). This subgroup
is termed treatment-resistant schizophrenia (TRS). The most common clinical and research
criteria used for TRS is the failure to respond to two trials of non-clozapine antipsychotics,
of adequate dose and duration (Suzuki et al., 2011; Howes et al., 2017).
Patients with TRS have higher rates of unemployment, worse quality of life, and poorer
social and occupational functioning than people who respond to treatment (Iasevoli et al.,
2016). Researchers have estimated that the direct healthcare costs for TRS in the US is
3–11-fold higher than for the schizophrenia population as a whole, with multiple hospitalisa-
tions accounting for a large proportion of this cost (Kennedy et al., 2014). In England, 25–50%
of the National Health Service’s (NHS) £11.8 billion mental health budget is allocated to
schizophrenia services and TRS is thought to contribute a large proportion of these costs
(Andrews et al., 2012; Killaspy et al., 2013).
Clozapine is the only antipsychotic recommended for TRS and is more effective than other
antipsychotics in alleviating psychotic symptoms in patients with TRS (Kane et al., 1988;
Siskind et al., 2016; Taylor, 2017). However, owing to its adverse effects, clozapine is only
licenced in the UK (NICE, 2014) and most other developed countries (Warnez and
Alessi-Severini, 2014) as a third-line treatment. Nevertheless, evidence suggests that TRS is
often not recognised promptly, and that clozapine is offered after a delay of some years or
not at all. According to treatment guidelines, the earliest that patients can be diagnosed
with TRS, and prescribed clozapine, is 12 weeks after commencing antipsychotic treatment;
however, Howes et al. (2012) report an average delay of 3.9 years, suggesting that there is con-
siderable scope to shorten this period of inadequate treatment. Furthermore, patients with a
shorter delay before clozapine initiation show a better symptomatic response to clozapine
(Yoshimura et al., 2017).
Thus, there is a need to identify patients-who are likely to develop TRS-earlier in the course
of their illness and expedite their access to specialist treatment; this may require moving
beyond the current definition of TRS towards criteria based upon predictors and biomarkers,
which quantify a patient’s risk of developing TRS. If predictors of TRS can be identified, they
may be useful in three ways: firstly, to identify TRS patients earlier in treatment so that they
can be offered effective treatments earlier; secondly, to identify patients for clinical trials of
interventions for TRS; and thirdly, to improve our understanding of the aetiology of TRS.
We present a comprehensive systematic review of all prospective observational studies in
schizophrenia populations, which report baseline predictors of TRS. We focused solely on pro-
spective observational studies to draw clearer conclusions regarding the causal relationship
https://doi.org/10.1017/S0033291719002083
Downloaded from https://www.cambridge.org/core. King's College London, on 22 Nov 2019 at 16:14:33, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms.
between predictors and TRS in naturalistic settings over a long
follow-up, and because only longitudinal studies can identify
risk factors at first episode that might predict TRS.
Method
Inclusion/exclusion criteria
Studies were included if they met the following inclusion criteria:
(1) participants were diagnosed with schizophrenia, schizophreni-
form disorder, schizoaffective disorder, and/or a psychotic dis-
order; we did not exclude studies that also included affective
disorders or substance-induced psychosis, given the diagnostic
uncertainly around the first episode of psychosis; (2) participants
were followed from the first episode or first treatment with anti-
psychotics; (3) the majority of participants were aged between 16
and 64 at baseline (we excluded studies that focused exclusively on
children or older adults); (4) data were collected prospectively
from the first episode; (5) the outcome was a categorical definition
of TRS, established using longitudinal prospective medication his-
tory; and (6) a non-TRS comparison group was recruited and fol-
lowed up in the same manner as the TRS group. Studies were
excluded if (1) they were clinical trials, or if non-antipsychotic
treatments, such as CBT or ECT, were administered as part of
the study procedure; (2) the study focussed exclusively on early
or late-onset schizophrenia; or (3) inferential statistics measuring
the association between baseline variables and TRS were not
reported, and our subsequent requests to the authors for unpub-
lished data were unsuccessful.
Defining TRS
Only recently has attention been given to the standardisation of
TRS criteria (Farooq et al., 2013; Suzuki et al., 2012; Lee et al.,
2015; Howes et al., 2017); therefore, we did not restrict studies
to one definition of TRS. We did, however, only include studies
with a categorical definition of TRS to capture the key underlying
concept-at least two treatment failures – and differentiate TRS
from relative measures of response/nonresponse. If patients took
clozapine at follow-up, we inferred that they met criteria for
TRS. Clozapine prescription is likely to underestimate the true
proportion of patients with TRS (Howes et al., 2012), but it is a
pragmatic criterion, since clozapine is only used for TRS, except
in very rare indications (e.g. psychosis in the context of
Parkinson’s disease or for people who suffer severe side-effects
to other antipsychotics).
Literature search
Studies were identified by searching Pubmed, PsychINFO (up to
October 2017), Medline (up to October 2017), Embase (up to
October 2017), and OpenGrey on the 1 November 2017. In add-
ition, we examined the first 20 pages of Google Scholar using
terms ‘predictor AND treatment-resistant AND schizophrenia’
on 3 January 2018. No restrictions were placed on the publication
date, but searches were restricted to the titles and abstracts of
papers (and subject headings in Medline, Embase, and
PsychINFO), studies published in English, and studies using
human participants. Search terms for Pubmed were as follows:
‘((treatment resistant) OR (treatment resistance) OR (treatment
refractory)) AND (schizophrenia) AND ((longitudinal) OR (pro-
spective))’. Search strategies for other databases can be found in
Appendix 1. We screened the title and abstracts of all identified
studies and then performed full-text screening of all potentially
eligible studies. Potentially eligible studies were cross-referenced;
additional relevant studies were identified by hand-searches of
the references, and by screening papers which had previously
cited these studies. Each additional paper was also hand-searched
until no new studies were identified. When full-text articles were
not available, the corresponding author was contacted. Author
SES conducted the initial screening, with APK independently
screening the studies identified through database searches and
all studies identified through cross-referencing.
Quality assessment
We followed the PRISMA guidelines for reporting systematic
reviews (Liberati et al., 2009).
Study quality was assessed using the Newcastle-Ottawa Scale
(NOS) for cohort studies (http://www.ohri.ca/programs/clinical_
epidemiology/oxford.asp). Eight items measure the selection, com-
parability, and outcome of each study. These items were modified
for this review, for example, follow-up needed to have been longer
than one year to score on the item concerning adequate duration
of follow-up (see Appendix 2). Authors SES and APK independ-
ently rated each study on the NOS (Appendix 3), any differences
in rating were discussed between authors and final ratings were a
consensus.
When available, we report adjusted hazard (HR) or odds ratios
(OR) with 95% confidence intervals (95% CI) in parentheses, for
predictors measured at baseline.
Results
A total of 12 studies were identified for inclusion in this review.
Study screening is depicted in Fig. 1 and a summary of the num-
ber of participants recruited into each study is presented in
Table 1. Database searches identified 545 records, 293 of which
were duplicates and removed. A total of 252 records were screened
and 248 were excluded. The main reasons for exclusion were: the
study did not follow participants from the first episode or first
treatment with antipsychotics (31%), participants recruited after
TRS had been identified (29%), and an outcome other than
TRS was reported (23%). The remaining four records were exam-
ined in more detail, as were the eight records identified by cross-
referencing. Only duplicates were identified through Google
Scholar. Of the 12 studies, 11 were published in peer-reviewed
academic journals. One study was unpublished (Chan et al.,
2014), however, after corresponding with the authors, a full report
was identified on the funding body’s website containing enough
information to be included in this review (https://rfs1.fhb.gov.
hk/app/fundedsearch/projectdetail.xhtml?id=1363).
Of the 12 included studies, eight presented original data and
four presented data on additional exposures within the same
cohort as a previous study, or a subset thereof. Of these eight,
three were population cohort studies. Both Sorensen et al.
(2014) and Wimberley et al. (2016b) used Danish population reg-
isters: data was extracted from multiple national databases and
linked using a unique personal identification number.
Additional analyses of Wimberley et al. (2016b)’s data tested
whether urbanicity (Wimberley et al., 2016a), the polygenic risk
score for schizophrenia (PRS-SZ; Wimberley et al., 2017), func-
tioning (Horsdal et al., 2017b), and C-reactive protein levels
(Horsdal et al., 2017a) could predict TRS. The third population
2 S. E. Smart et al.
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cohort came from South Korea (Kim et al., 2017). The remaining
five studies analysed longitudinal first episode psychosis patient
cohorts (Meltzer et al., 1997; Chan et al., 2014; Lally et al.,
2016; Üçok et al., 2016; Demjaha et al., 2017).
In population registries, a proxy definition of first-episode
psychosis is required. In the Danish studies, the first
International Classification of Diseases (ICD; World Health
Organization, 1993) diagnosis of schizophrenia was used to define
the baseline cohort. The South Korean study used ICD diagnosis
of schizophrenia and the first use of antipsychotics to define the
baseline cohort. When using diagnoses, the first episode is likely
to be later in the disease course, when compared to cohort studies.
Additional study characteristics, including information about
recruitment, diagnoses, and criteria for TRS and non-TRS can
be found in Appendix 4. The variables measured, and tested as
predictors of TRS, varied considerably across studies, therefore
this information is summarised in Table 2. Appendix 5 contains
the unadjusted and adjusted OR/HR, when these were reported.
Predictors of TRS
Chan et al. (2014) analysed a subsample of a first episode cohort
who presented to mental health services over a five-year period
and used clozapine prescription as a definition of TRS. As this
was a case-control study including all patients with TRS and a
ratio of two non-TRS patients for every TRS patient, the
Fig. 1. PRISMA flow diagram.
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prevalence of TRS could not be calculated. The two groups were
matched on baseline diagnosis. Chan et al. (2014) included age of
onset, duration of untreated psychosis (DUP; days), duration of
first episode, years of education, Premorbid Adjustment Scale
(PAS) adult (19 + years) subscale score (Cannon-Spoor et al.,
1982), substance misuse history, and the number of relapses in
the first three years, in a Cox proportional hazard regression.
The model significantly predicted TRS (Chi-square = 66.11,
df = 7, p = <0.0001). While number of relapses in the first three
years significantly predicted TRS, the only baseline predictors sig-
nificantly associated with TRS were younger age of onset (HR =
0.88, 95% CI = 0.83–0.94) and poorer premorbid functioning
(indicated by higher scores) according to the PAS (HR = 3.22,
95% CI = 1.43–7.23).
Demjaha et al. (2017) analysed data from the AESOP study,
which recruited first episode patients over a three-year period
and followed them up ten years later. The researchers entered
gender, diagnosis, age of onset, negative symptoms, mode of
onset, DUP (weeks), and ethnicity into a multivariate penalised
logistic regression. The model selected five variables that predicted
TRS: a diagnosis of schizophrenia at baseline (instead of psychotic
depression; OR = 0.41, or psychotic mania; OR = 0.52), younger
age of onset (years, OR = 0.97), higher severity of negative symp-
toms (OR = 1.09), an insidious mode of onset (instead of acute;
OR = 1.28), and longer DUP (OR = 1.0013). Goodness-of-fit was
measured using McFadden’s pseudo R2 and correct classification
rates were measured using the Brier score. A McFadden’s pseudo
R2 between 0.20 and 0.40 is considered a good model fit. The
Brier score is used to evaluate predictive models; if the incidence
of TRS is 23%, as estimated from Demjaha et al. (2017), a Brier
score of 0 would be a perfect model while a score of 0.177
would be a non-informative model (Steyerberg et al., 2010).
Demjaha et al. (2017) reported a McFadden’s pseudo R2 of 0.10
and a Brier score of 0.146, suggesting that their model is not a
good fit of the data nor is it a good classifier of TRS.
Kim et al. (2017), in their South Korean population cohort,
estimated the cumulative incidence of clozapine use using the
Kaplan–Meier method and log-rank test. They reported that
younger age of onset predicted TRS. Unlike Chan et al. (2014)
and Demjaha et al. (2017), Kim et al. (2017) examined age of
onset categorically: defining younger age of onset as those aged
between 15–20 years of age, and comparing them to a
middle-onset group (21–44 years of age) and a late-onset group
(45–64 years of age). Kim et al. (2017) also found, using the
Walter–Elwood method (Walter and Elwood, 1975), a higher
incidence of clozapine use, in those born during winter
(December to February) when compared to those born in sum-
mer (June to August). This pattern remained true when stratifying
season of birth by age of onset. Kim et al. (2017) reported no
measures of overall model fit.
Lally et al. (2016) recruited first episode patients over a five-
year period and used electronic medical records to follow them
up five years later. They entered age of onset, Positive and
Negative Symptom Scale (PANSS; Kay et al., 1987) scores,
Global Assessment of Functioning (GAF; Hall, 1995) disability
score, and GAF symptom scores into a penalised logistic regres-
sion, controlling for living arrangements, employment status,
and alcohol/substance misuse during the follow-up period. Lally
et al. (2016) included the PANSS total score, the positive, negative
and general psychopathology subscale scores, as well as two indi-
vidual items: lack of insight and conceptual disorganisation. None
of the PANSS or GAF variables predicted TRS. Age at first contact
with mental health services was split into four categories: 18–20,
21–25, 26–30, >31 years. Only age of onset between 18 and 20
years, compared to all other age groups, significantly predicted
TRS (OR = 2.49, 95% CI = 1.25–4.94). The authors did not report
the overall model fit. Age of onset was subsequently stratified by
gender and ethnicity. Age of onset, between 18 and 20, only pre-
dicted TRS in males (OR = 2.13, 95% CI = 1.35–7.23) or those of
black ethnicity (OR = 3.71, 95% CI = 1.44–9.56).
Meltzer et al. (1997) recruited patients at first admission to
hospital for schizophrenia or schizoaffective disorder and fol-
lowed them up for approximately four years. The authors exam-
ined the age of onset and gender in relation to TRS using a
two-way analysis of variance (ANOVA). Gender was not asso-
ciated with TRS but younger age of onset was. As males had a
Table 1. The twelve studies included in this review, with details on the number of participants recruited and the length of follow-up
Study
Number of participants
Length of follow-up (years)Baseline Follow-up (%) TRS (%) Non-TRS (%)
Chan et al. (2014) 469 469 (100) 160 (34) 309 (66) 16
Demjaha et al. (2017) 557 274 (49) 62 (23) 212 (77) 10
Horsdal et al. (2017a)* 390 390 (100) 52 (13) 338 (87) 2
Horsdal et al. (2017b)* 3252 3252 (100) 359 (11) 2893 (89) 2
Kim et al. (2017) 114 749 NR NR NR NR
Lally et al. (2016) 283 240 (85) 81 (34) 159 (66) 5
Meltzer et al. (1997) 322 322 (100) 196 (61) 126 (39) 4
Sorensen et al. (2014) 5968 5328 (89) 1223 (23) 4105 (77) 34
Üçok et al. (2016) 187 105 (56) 28 (27) 77 (73) 2
Wimberley et al. (2016a)* 13 349 13 349 (100) 2313 (17) 11 036 (83) 17
Wimberley et al. (2016b) 9332 8044 (86) 1703 (21) 6341 (79) 14
Wimberley et al. (2017)* 862 862 (100) 181 (21) 681 (79) 11
NB: NR, not reported; *, analysis of data also presented in Wimberley et al. (2016b)
4 S. E. Smart et al.
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Table 2. The variables which have been tested as predictors of TRS in the twelve studies included in this review
Chan
et al.
(2014)
Demjaha
et al. (2017)
Kim
et al.
(2017)
Lally
et al.
(2016)
Meltzer
et al.
(1997)
Sorensen
et al. (2014)
Üçok
et al.
(2016)
Wimberley
et al. (2016b)
Younger age of onset
Alcohol misuse during
follow-up period
Antipsychotic
polypharmacy during
follow-up period
C‐reactive protein
Comorbid diagnosis of
personality disorder
Comorbid diagnosis of
suicide attempts
Schizophrenia
diagnosis
Paranoid
schizophrenia
diagnosis
Duration of first
episode
Longer DUP
Early parental loss
Lower education
qualification
Fewer years in
education
Employment status
Black ethnicity
Family history of
schizophrenia
Worse functioning
Worse premorbid
functioning
Male
Living arrangements
Living arrangements
during follow-up
period
Marital status
Mode of onset
Paternal age
Polygenic risk score for
schizophrenia
Relapse despite
adherence
Relapse in first 6
months
More relapses in the
first three years
Born in Autumn/winter
Substance misuse
(Continued )
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younger age of onset than females, the researchers examined the
associations between age of onset and gender in more depth using
simple effects ANOVA. In the non-TRS group, males had a
younger age of onset (F = 6.6, df = 1, p < 0.01), however, in the
TRS group, there was no difference in age of onset between
males and females. Meltzer et al. (1997) calculated the conditional
probability of a patient having TRS given their age of onset. For
those aged between 15 and 18 years old, the probability of devel-
oping TRS was between 32% and 38% for both males and females.
Sorensen et al. (2014), in their Danish population cohort,
entered a season of birth into a Cox proportion hazard regression
adjusted for birth year and gender. The model did not signifi-
cantly predict TRS. However, the authors found that being born
in autumn (September to November), compared to spring
(March to May), predicted TRS (HR = 1.24, 95% CI = 1.06–
1.46). Unlike in Kim et al. (2017)’s study, being born in winter
(December to February) failed to predict TRS.
Üçok et al. (2016) analysed a subsample of patients recruited
into an ongoing first episode schizophrenia study. Üçok et al.
(2016) entered the age of onset, DUP (days), first relapse despite
adherence to antipsychotic treatment, relapse in the first six
months, and antipsychotic polypharmacy during follow-up, into
logistic regression. The authors did not report the overall model
fit. Only first relapse despite adherence to antipsychotic treatment
and antipsychotic polypharmacy predicted TRS. No baseline vari-
ables predicted TRS.
Wimberley et al. (2016b), in their Danish population cohort,
entered twenty-three variables into a Cox proportion hazard
regression. These variables included: gender, age at first schizo-
phrenia diagnosis as a proxy for age of onset, family history of
schizophrenia in first-degree relatives, winter birth (December
to March), paternal age, parental loss before the age of 18, living
alone, conviction for a violent offence before first schizophrenia
diagnosis, level of education, employment status, urbanicity at
first schizophrenia diagnosis, admission to psychiatric hospital
before first schizophrenia diagnosis, schizophrenia subtype (para-
noid v. all others), comorbid psychiatric diagnosis before first
schizophrenia diagnosis, antipsychotic prescription in the year
before first schizophrenia diagnosis, antidepressant prescription
in the year before first schizophrenia diagnosis, and benzodiazep-
ine prescription in the year before first schizophrenia diagnosis.
Goodness-of-fit was measured using McFadden’s pseudo R2 and
correct classification rates using Harrell’s C statistic; a C statistic
of 0.5 would be a non-informative model while a score of 1
would be a perfect model. Wimberley et al. (2016b) report a
McFadden’s pseudo R2 of 0.027 and a Harrell’s C statistic of
0.70, suggesting that this model is a good fit of the data and rea-
sonable classifier of TRS. At baseline, younger age of onset (years,
HR = 0.96, 95% CI = 0.95–0.97), living in less urban areas (rural v.
capital area, HR = 1.44, 95% CI = 1.25–1.65), higher education
(higher v. primary education, HR = 0.88, 95% CI = 0.79–0.98),
psychiatric hospital admission at diagnosis (HR = 2.07, 95% CI
= 1.87–2.29), having spent more than 30 bed-days in a psychiatric
hospital in the year before diagnosis (HR = 1.54, 95% CI = 1.35–
1.75), paranoid subtype diagnosis (HR = 1.24, 95% CI = 1.13–1.37),
comorbid personality disorder (HR = 1.24, 95% CI = 1.11–1.39),
comorbid suicide attempt (HR = 1.21, 95% CI = 1.07–1.39), anti-
psychotic use (HR = 1.51, 95% CI = 1.35–1.69), antidepressant use
(HR = 1.15, 95% CI = 1.03–1.29), and benzodiazepines use (HR =
1.22, 95% CI = 1.10–1.37), all predicted TRS. Data on additional
exposures within the same cohort, or a subset thereof, were pub-
lished separately. Lower levels of urbanicity (Wimberley et al.,
2016a) and severely impaired functioning (a GAF functioning
score ⩽30; Horsdal et al., 2017b) predicted TRS, but the polygenic
risk score for schizophrenia (PRS-SZ; Wimberley et al., 2017) and
C-reactive protein levels (Horsdal et al., 2017a) did not predict TRS.
Subcategories of TRS
Some patients have little or no response to antipsychotic treat-
ment from the onset of their illness, while others initially respond
to medication and then later develop TRS. Two of the studies in
our review reported comparisons between subgroups TRS
patients; early-onset TRS was operationalised as meeting criteria
for TRS from the onset of schizophrenia and delayed-onset TRS
as meeting criteria after a period of symptomatic remission.
Chan et al. (2014) found no differences, in demographics, clinical
characteristics, or premorbid functioning, between early-onset
Table 2. (Continued.)
Chan
et al.
(2014)
Demjaha
et al. (2017)
Kim
et al.
(2017)
Lally
et al.
(2016)
Meltzer
et al.
(1997)
Sorensen
et al. (2014)
Üçok
et al.
(2016)
Wimberley
et al. (2016b)
Substance misuse
during follow-up
period
More symptoms of
psychosis
Inpatient
Urbanicity at birth
Living in a more rural
area at diagnosis
Violent offence
Chan
et al.
(2014)
Demjaha
et al. (2017)
Kim
et al.
(2017)
Lally
et al.
(2016)
Meltzer
et al.
(1997)
Sorensen
et al. (2014)
Üçok
et al.
(2016)
Wimberley
et al. (2016b)
NB: grey squares, variables not significantly associated with TRS; dark grey squares, variables significantly associated with TRS; all analyses using the Wimberley et al., Danish dataset were
grouped under Wimberley et al. (2016b)
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TRS (N = 17, 11.64%) and delayed-onset TRS (N = 129, 88.36%).
Lally et al. (2016) found no differences in demographics between
the two groups, but the early-onset TRS group (N = 56, 70%) had
a younger mean age of onset than the delayed-onset TRS group
(N = 24, 30%).
Discussion
This review identified twelve research papers that examined pre-
dictors of TRS. Seven of the studies included in this review tested
the age of onset as a predictor, and six reported that younger age
of onset predicted TRS. Given that multiple definitions of the age
of onset – age of onset of psychotic symptoms, age of first diag-
nosis of schizophrenia, age of first contact with mental health
services – were reported and data was treated both continuously
and categorically, this is a robust finding. Other potential risk fac-
tors, that have been identified by more than one study, include
diagnosis, level of functioning, male gender, and season of birth.
A recent meta-analysis linked younger age of onset to multiple
poor outcomes in schizophrenia: more hospitalisations, more
negative symptoms, more relapses, poorer social/occupational
functioning, and poorer global outcome (Immonen et al., 2017).
Many of these poor outcomes have also been associated with
TRS. Immonen et al. (2017) found that males had a younger
age of onset and, therefore, samples with a higher proportion of
males tended to show stronger associations between age of
onset and outcomes. In the studies included in this review, the
association between age of onset and TRS is unlikely to be wholly
confounded by gender, as the proportion of males ranged from
49% (Kim et al., 2017) to 67% (Lally et al., 2016) and the studies
which controlled for gender still showed an effect of age of onset
(Meltzer et al., 1997; Lally et al., 2016; Wimberley et al., 2016b;
Demjaha et al., 2017). In schizophrenia, age of onset has been
thought to reflect genetic liability for the disease; younger age
of onset has been associated with an increased familial risk of
schizophrenia (Hilker et al., 2017; Byrne et al., 2018). Could,
therefore, TRS be the result of increased genetic risk? While
Wimberley et al. (2017) found no association between PRS-SZ
and TRS, other work published by Frank et al. (2014) reports
that an increased PRS-SZ is associated with TRS. In addition,
rare copy number variations have been associated with both
TRS (Martin and Mowry, 2015) and childhood-onset schizophre-
nia (Addington and Rapoport, 2009). Therefore, patients with
TRS, who also have a younger age of onset, may have a more sali-
ent genetic influence than later-onset cases, although further work
is required to substantiate this claim.
This review complements previous reviews by Gillespie et al.
(2017) and Carbon and Correll (2014). Gillespie et al. (2017) exam-
ined studies comparing patients with treatment-resistant to patients
with treatment-responsive schizophrenia. They included all study
methodologies, but excluded studies where treatment-responsiveness
was defined solely as not meeting treatment-resistant criteria.
Carbon and Correll (2014) examined studies identifying predictors
of response and remission. The researchers focused on first-episode
psychosis studies where participants were followed up for five years.
Some of the predictors of TRS, identified in this review, were found
to be associated with less chance of response/remission by Carbon
and Correll (2014), e.g. younger age of illness onset, poor premorbid
adjustment, being male, lower level of education, living in a rural
environment, diagnosis of schizophrenia, longer duration of
untreated psychosis, poorer functioning, and worse psychopath-
ology. However, Carbon and Correll (2014) also associated less
chance of response/remission with being single, family history of
psychosis, greater cognitive dysfunction, more family conflicts, and
substance misuse; characteristics not identified as predictors of
TRS. There was relatively little overlap between this review and
Gillespie et al. (2017)’s review. In terms of studies included, only
Meltzer et al. (1997)’s study was included in both reviews. In
terms of characteristics associated with TRS, Gillespie et al. (2017)
identified five neuroimaging studies, nine gene-association studies,
and two studies of neurocognitive function, and these studies were
not included in our review. The examination of biological markers,
associated with TRS, within longitudinal study designs is rare; this is
understandable for genome-wide association studies, which require
large sample sizes more easily acquired using a cross-sectional meth-
odology. However, there is a clear gap in the literature investigating
biological markers that change over time (for example, proinflam-
matory cytokines or differently methylated positions within the epi-
genome) and TRS as an outcome. In terms of neuroimaging
research, a review by Nakajima et al. (2015) found only five studies
which compared patients with TRS to non-TRS patients, none of
which had identified neural correlates of TRS. McGuire and
Dazzan (2017) highlight only one study where neuroimaging data
predicted a six-year, non-remitting course of illness. Longitudinal
imaging studies of TRS are still relatively rare and constitute another
gap in the literature.
Of the studies included in this review, few identified character-
istics of abnormal neurodevelopment as predictors of TRS, despite
neurodevelopment changes being linked with schizophrenia. The
neurodevelopmental theory of schizophrenia proposes that dis-
rupted normal development, in utero or early infancy, leads to def-
icits in psychophysiological and neurological functioning in
childhood or early adolescence, and eventually to prodromal or
diagnostic symptoms of schizophrenia (Jablensky et al., 2017;
Murray et al., 2017). Previous research has linked characteristics
of abnormal development with TRS; higher rates of minor physical
anomalies (Lin et al., 2015), more neurological soft signs (de
Bartolomeis et al., 2018), poor verbal intelligence and fluency
(Kravariti et al., 2018), and poor verbal memory (Joober et al.,
2002; de Bartolomeis et al., 2013). None of the studies in this review
included variables measuring physiology during development or
cognition at the first episode. Only Chan et al. (2014) examined
premorbid functioning, retrospectively using the PAS. They
found no difference, between the TRS and non-TRS groups, in
terms of functioning during childhood, early adolescence, or late
adolescent. There was a difference in functioning after the age of
19 and subsequently, worse functioning predicted TRS in their
final model. If educational attainment can be considered a proxy
for development only lower level of education qualification was
found to significantly predict TRS (Wimberley et al., 2016b). The
number of years in education was not predictive of TRS (Chan
et al., 2014). Abnormal neurodevelopment and neuropsychology
have not been sufficiently investigated as potential predictors of TRS.
Our review has illuminated some gaps in the existing literature,
where potential predictors have not been fully investigated, however,
we believe our review has captured all published work and identified
predictors that, with further study, may prove to be clinically useful
in determining treatment for patients with schizophrenia.
Strengths and limitations
The main strength of this review is that we have focused solely on
studies that included temporal forecasting (observations at base-
line that are used to predict outcomes at follow-up), and as
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such eliminated recall bias and established a key component
necessary for predictive models. All the studies included in this
review are likely to be sufficiently powered to detect predictors
of TRS. All the studies reported large sample sizes, and most fol-
lowed participants for more than one year. Although no studies
reported a priori power analysis, and only Meltzer et al. (1997)
reported an ad hoc power analysis, we believe lack of power is
unlikely to explain these results.
When attrition reduces the sample size at follow-up of longi-
tudinal studies, consequently, statistical power is also reduced.
For the studies we have reviewed, that reported on participants
lost to follow-up, it is unlikely that the low attrition rates intro-
duced bias. In particular, many studies used Cox proportional
hazard regression; an analytic method that not only takes into
account that individuals lost to follow-up may develop TRS, but
also that individuals may develop TRS after the study endpoint.
However, TRS, in particular, may be biased by attrition. There
is a case both that TRS patients may be more likely to drop out
of research studies due to their higher severity of symptoms
and worse social and occupational functioning, and that respon-
ders are more likely to drop out as they lose touch with clinical
services, but we are not aware of any published studies examining
attrition in relation to treatment response.
One limitation to consider, when discussing the findings from
these studies, is that some patients may have been misclassified.
None of the studies included in this review explicitly accounted
for adherence to medication, therefore characteristics may be pre-
dicting nonadherence rather than treatment resistance. None of
the studies measured antipsychotic plasma levels, therefore charac-
teristics may be predicting sub-therapeutic drug plasma levels, as a
consequence of nonadherence, noncompliance, or pharmacokinet-
ics, rather than treatment resistance. McCutcheon et al. (2015)
found that 44% of patients referred to an outpatient service for clo-
zapine treatment had sub-therapeutic conventional-antipsychotic
plasma levels. On the other hand, it is unlikely that TRS patients
have been wrongly classified as responders because the long
follow-up periods allow plenty of time for a diagnosis of TRS to
be established. Most studies had follow-ups longer than four
years; the average delay before being treated for TRS estimated
by Howes et al. (2012). The definitions of TRS, used in these stud-
ies, are pragmatic criteria: any predictors identified by these natur-
alistic studies are generalisable to real-world, clinical settings where
adherence, compliance, or drug plasma levels influence treatment.
The use of multiple definitions of TRS is a problem across all
TRS literature; Suzuki et al. (2011) reviewed 33 studies of pro-
spective studies of pharmacological interventions for TRS and
found that all 33 definitions of TRS were different. Howes et al.
(2017) reviewed 42 clinical trials and found only two studies
which used identical criteria. In addition, some studies use cloza-
pine prescription as a proxy for TRS. When clozapine is under-
prescribed, supposed predictors of TRS may, in fact, represent
predictors of clozapine initiation (e.g. clinicians’ attitudes towards
clozapine prescription). All of the studies, identified in this review,
used existing data, not designed to examine TRS, and researchers
had to established proxy definitions based on the data available to
them. When evidence concerning predictors of TRS is not con-
sistent, it can be hard to draw a clear conclusion about the validity
of the predictor, yet when the evidence is consistent across stud-
ies, with different definitions, the predictor in question is highly
likely to generalise to other cohorts and have clinical validity.
Finally, we must consider the statistical methodology used to
establish predictors. A common misconception is that predictive
accuracy can be inferred from explanatory accuracy. However,
the two are different and should be assessed separately
(Shmueli, 2010). Only three studies included in this review
reported the overall model fit, and only two reported statistics
that measure the predictive validity of the model. Additionally,
in predictive modelling, variable selection and overfitting must
be considered. Lally et al. (2016) and Demjaha et al. (2017)
attempted to reduce overfitting by penalising regression coeffi-
cients. However, none of the studies used holdout data (training
data), cross-validation, or external validation to evaluate the pre-
dictive power of models; the latter being the current ‘gold-
standard’ approach. In terms of variable selection, the only meth-
ods reported were LASSO regression (Demjaha et al., 2017) and
step-wise selection using statistical significance (Chan et al.,
2014; Üçok et al., 2016). Stepwise methods are no longer consid-
ered appropriate for explanatory models, but stepwise-type algo-
rithms are very useful in predictive modelling (Shmueli, 2010),
as long as the selection criteria rely on predictive power (e.g.
Akaike information criterion) rather than explanatory power
(e.g. statistical significance), as was the case in these studies.
These methodological limitations must be taken into consider-
ation when evaluating predictive models. The studies included
in the review, on the whole, report analyses designed to identify
explanatory variables of TRS. Future studies will need to use
more robust prediction methods before moving from statistical
prediction to clinical prediction.
Conclusion
The aim of this systemic literature review was to identify predic-
tors of treatment-resistant schizophrenia from prospective longi-
tudinal studies. In choosing to focus exclusively on longitudinal
studies, we have filled a gap in the existing literature, and hope
that consolidating this information will be of use to researchers
attempting to identify clinical predictors of TRS and the biological
mechanisms causing TRS. We have identified earlier age of
schizophrenia-onset as a robust predictor of TRS, with evidence
that male gender, autumn/winter birth, poor premorbid functioning
and rural upbringing may also contribute. We have also highlighted
gaps in the literature namely, studies examining neuroimaging,
immune, and genetic markers of TRS. Examination of biological
markers, particularly within the framework of a prospective longitu-
dinal study, has the potential to go beyond simple prediction and
add to our understanding of the underlying causes of TRS. In con-
clusion, while early identification of TRS is clinically important, we
currently have very limited knowledge of its predictors.
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